Bioxcel therapeutics announces proposed public offering

New haven, conn., nov. 21, 2024 (globe newswire) -- bioxcel therapeutics, inc. (the “company”) (nasdaq: btai), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it has commenced an underwritten public offering of shares of its common stock, par value $0.001 per share (“common stock”), and accompanying warrants to purchase shares of common stock, and, in lieu thereof to certain investors that so choose, pre-funded warrants to purchase shares of common stock and accompanying warrants to purchase shares of common stock.
BTAI Ratings Summary
BTAI Quant Ranking